Inhaled Triple Therapy with Extrafine Single Inhaler Versus Multiple Devices in Chronic Obstructive Pulmonary Disease (TRIPOLI): A Post-Authorization Retrospective Study
International Journal of Chronic Obstructive Pulmonary Disease · 2025
DOI: 10.2147/copd.s513351 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Eva Cabrera César und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonology Department, Virgen de la Victoria University Hospital, Málaga, Spain. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Glycopyrrolate, Beclomethasone, Formoterol Fumarate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Chiesi S.A.U.
Themen: COPD
Abstract (Originalsprache)
Background
Triple therapy significantly enhances both clinical and functional outcomes in patients with uncontrolled chronic obstructive pulmonary disease (COPD), even when they are already receiving treatment. However, it is often prescribed with multiple inhalers, which can affect adherence to treatment. The evidence on the effectiveness of extrafine single inhaler triple therapy (efSITT) compared to multiple inhalers triple therapy (MITT) in patients with moderate-to-severe COPD in the real-world setting is limited.
Methods
TRIPOLI was a unicentric retrospective observational study that compared one year of efSITT with beclomethasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium with one year of MITT in terms of exacerbations, use of rescue medication, adherence, and lung function in patients with COPD.
Results
A total of 71 patients were analyzed. The mean number of total and moderate exacerbations showed a significant reduction of 27.56% (p = 0.0043) and 29.56% (p = 0.0008), respectively, after efSITT. The percentage of patients with poor adherence decreased from 30.2% to 9.9% with efSITT and the proportion of patients with complete adherence increased from 55.8% to 81.7%. An improvement of 2.29% was described in mean forced expiratory volume in the first second (% pred). No differences were observed in the rate of pneumonia between the treatment with efSITT and MITT.
Conclusion
The TRIPOLI study suggests that switching from MITT to efSITT might reduce exacerbations in patients with moderate-to-severe COPD, likely attributable to improved adherence in real-world settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonology Department, Virgen de la Victoria University Hospital, Málaga, Spain.
- Chiesi España, Barcelona, Spain.
ORCID-Profile: Diego González-Segura Alsina
Förderung
- Chiesi S.A.U
Zitieren
APA
Cabrera César, E., López García, J., Vega Lizarazo, D. E., Benítez-Cano Gamonoso, M., Segura Romero, M., Sanchez Martín, S., León Nieto, M. I., González-Segura Alsina, D., & Velasco Garrido, J. L. (2025). Inhaled Triple Therapy with Extrafine Single Inhaler Versus Multiple Devices in Chronic Obstructive Pulmonary Disease (TRIPOLI): A Post-Authorization Retrospective Study. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s513351
Vancouver
Cabrera César E, López García J, Vega Lizarazo DE, Benítez-Cano Gamonoso M, Segura Romero M, Sanchez Martín S, et al. Inhaled Triple Therapy with Extrafine Single Inhaler Versus Multiple Devices in Chronic Obstructive Pulmonary Disease (TRIPOLI): A Post-Authorization Retrospective Study. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s513351
BibTeX
@article{CabreraCsar2025,
author = {Cabrera César, Eva and López García, Javier and Vega Lizarazo, Daniel Enrique and Benítez-Cano Gamonoso, Miguel and Segura Romero, Mercedes and Sanchez Martín, Sara and León Nieto, Mónica I and González-Segura Alsina, Diego and Velasco Garrido, José Luis},
title = {Inhaled Triple Therapy with Extrafine Single Inhaler Versus Multiple Devices in Chronic Obstructive Pulmonary Disease (TRIPOLI): A Post-Authorization Retrospective Study},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2025},
doi = {10.2147/copd.s513351}
}
EUVIMED